Despite not differentiating itself from placebo, the Texas-based company said it plans to push pilavapadin into Phase III ...

The company has chosen to move ahead to Phase III trials with its 10mg dose after it saw a 1.74-point reduction in pain score ...

Lexicon Pharmaceuticals is yet again defending a mixed set of data on its non-opioid pain prospect. | Lexicon Pharmaceuticals ...

Mexico has handled the cartels so poorly that it broke international law. It is obligated to prevent the harm cartels are ...

Vertex Pharmaceuticals Incorporated ( NASDAQ: VRTX) TD Cowen 45th Annual Health Care Conference Transcript March 3, 2025 3:10 PM ET David Altshuler - Executive Vice President, Global Research and CSO ...

The Food and Drug Administration (FDA) has granted Fast Track designation to LTG-001 for the treatment of acute pain. LTG-001, an oral Nav1.8 selective ...

Over the 5 years following a single steroid injection, prescriptions for opioid-nonopioid combination products (e.g., ...

Shares of Lexicon Pharmaceuticals , Inc. (Nasdaq: NASDAQ: LXRX) plummeted 50% following the announcement of topline results from its Phase 2b PROGRESS study, whic ...

Investing.com -- Shares of Lexicon Pharmaceuticals , Inc. (NASDAQ: LXRX) tumbled 55% after the company announced topline results from its PROGRESS Phase 2b study, which evaluated pilavapadin in ...

Guilford County and local governments across the state are doing what they can to help substance abusers kick the habit – ...

Lexicon's non-opioid drug pilavapadin fails Phase 2b pain trial at 20mg dose, but shows promise at 10mg. Company plans Phase ...

The American Society of Anesthesiologists released new guidance on the safe use of ketamine for nonanesthesia purposes, such ...